Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 27, 2023

AVID200, a TGFβ 1/3 Protein Trap, in Patients With Myelofibrosis

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Clin. Cancer Res 2023 Jul 13;[EPub Ahead of Print], J Mascarenhas, AR Migliaccio, H Kosiorek, R Bhave, J Palmer, A Kuykendall, R Mesa, RK Rampal, AT Gerds, A Yacoub, K Pettit, M Talpaz, R Komrokji, M Kremyanskaya, A Gonzalez, F Fabris, K Johnson, M Dougherty, E McGovern, J Arango Ossa, D Domenico, N Farnoud, RS Weinberg, A Kong, V Najfeld, AM Vannucchi, F Arciprete, M Zingariello, M Falchi, ME Salama, C Mead-Harvey, A Dueck, L Varricchio, R Hoffman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading